Skip to main content
Top

04-04-2016 | Pediatric lymphoma | Article

Imaging of primary pediatric lymphoma of bone

Journal: Pediatric Radiology

Authors: Kathryn S. Milks, Thomas W. McLean, Evelyn Y. Anthony

Publisher: Springer Berlin Heidelberg

Abstract

Background

Primary pediatric bone lymphoma is a rare form of non-Hodgkin lymphoma. Unlike nodal forms of lymphoma, imaging abnormalities in lymphoma of bone do not resolve rapidly in conjunction with treatment and radiologic findings can remain abnormal for years, making it difficult to evaluate treatment response.

Objective

To evaluate the utility of imaging in assessment of patients with primary pediatric bone lymphoma.

Materials and methods

At our institution between 2004 and 2013, six cases of pathology-proven primary pediatric bone lymphoma were diagnosed. Retrospective chart review was performed to assess imaging utilization. Our data were qualitatively compared with existing literature to construct an algorithm for imaging patients with primary lymphoma of bone.

Results

Imaging evaluation of patients with primary pediatric bone lymphoma was highly variable at our institution. Conventional imaging was routinely used to evaluate response to treatment, despite lack of appreciable osseous change. Imaging in the absence of symptoms did not alter clinical management. Only positron emission tomography CT (PET/CT) proved capable of demonstrating imaging changes from the pretreatment to the post-treatment scans that were consistent with the clinical response to treatment.

Conclusion

Surveillance imaging is likely unnecessary in patients with a known diagnosis of pediatric lymphoma of bone. Pretreatment and post-treatment PET/CT is likely sufficient to assess response. There is little data to support the use of interim and surveillance PET/CT.
Literature
1.
Lones MA, Perkins SL, Sposto R et al (2002) Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol 20:2293–2301CrossRefPubMed
2.
Zhao XF, Young KH, Frank D et al (2007) Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases. Am J Clin Pathol 127:47–54CrossRefPubMed
3.
Ramadan KM, Shenkier T, Sehn LH et al (2007) A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 18:129–135CrossRefPubMed
4.
Suryanarayan K, Shuster JJ, Donaldson SS et al (1999) Treatment of localized primary non-Hodgkin's lymphoma of bone in children: a Pediatric Oncology Group study. J Clin Oncol 17:456–459PubMed
5.
Borowitz MJ, Wood BL, Devidas M et al (2015) Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood 126:964–971CrossRefPubMed
6.
Furman WL, Fitch S, Hustu HO et al (1989) Primary lymphoma of bone in children. J Clin Oncol 7:1275–1280PubMed
7.
Glotzbecker MP, Kersun LS, Choi JK et al (2006) Primary non-Hodgkin's lymphoma of bone in children. J Bone Joint Surg Am 88:583–594CrossRefPubMed
8.
Borst AJ, States LJ, Reilly AF, Rheingold SR et al (2013) Determining response and recurrence in pediatric B-cell lymphomas of the bone. Pediatr Blood Cancer 60:1281–1286
9.
Okada M, Sato N, Ishii K et al (2010) FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma. Radiographics 30:939–957CrossRefPubMed
10.
Ferrari C, Minoia C, Asabella AN et al (2014) Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma. Hell J Nucl Med 1:40–49
11.
Moog F, Bangerter M, Diederichs CG et al (1998) Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206:475–481CrossRefPubMed
12.
Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068CrossRefPubMed
13.
Elstrom RL, Leonard JP, Coleman M et al (2008) Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19:1770–1773CrossRefPubMedPubMedCentral
14.
Moog F, Kotzerke J, Reske SN (1999) FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 40:1407–1413PubMed
15.
Quarles van Ufford H, Hoekstra O, de Haas M et al (2010) On the added value of baseline FDG-PET in malignant lymphoma. Mol Imaging Biol 12:225–232CrossRefPubMed
16.
Herrmann K, Queiroz M, Huellner MW et al (2015) Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC Cancer 15:1002CrossRefPubMedPubMedCentral
17.
Yoo HJ, Lee JS, Lee JM (2015) Integrated whole body MR/PET: where are we? Korean J Radiol 16:32–49CrossRefPubMedPubMedCentral
18.
Pfluger T, Melzer H, Mueller W et al (2012) Diagnostic value of combined 18F-FDG PET/MRI for staging and restaging in paediatric oncology Eur J Nucl Med Mol Imaging 39:1745–1755
19.
Krishnasetty V, Bonab AA, Fischman AJ et al (2008) Comparison of standard-dose vs low-dose attenuation correction CT on image quality and positron emission tomographic attenuation correction. J Am Coll Radiol 5:579–584
20.
Cheson BD (2011) Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844–1854
21.
Abramson SJ, Price AP (2008) Imaging of pediatric lymphomas. Radiol Clin North Am 46:313–338, ixCrossRefPubMed
22.
Friedman DL, Chen L, Wolden S et al (2014) Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol 32:3651–3658CrossRefPubMedPubMedCentral
23.
Zhu D, Xu XL, Fang C et al (2015) Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis. Int J Clin Exp Med 8:15340–15350PubMedPubMedCentral
24.
Kaste SC, Shulkin BL (2006) 18F-Fluorodeoxyglucose PET/CT in Childhood Lymphoma. PET Clin 1:265–273CrossRefPubMed
25.
Jhanwar YS, Straus DJ (2006) The role of PET in lymphoma. J Nucl Med 47:1326–1334PubMed
26.
Zinzani PL, Stefoni V, Tani M et al (2009) Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 27:1781–1787CrossRefPubMed
27.
Jerusalem G, Beguin Y, Fassotte MF et al (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14:123–130CrossRefPubMed
28.
Cashen AF, Dehdashti F, Luo J et al (2011) 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 52:386–392CrossRefPubMedPubMedCentral
29.
Truong Q, Shah N, Knestrick M et al (2014) Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. Clin Lymphoma Myeloma Leuk 14:50–55CrossRefPubMed
30.
Thompson CA, Ghesquieres H, Maurer MJ et al (2014) Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol 32:3506–3512CrossRefPubMedPubMedCentral
31.
Mengiardi B, Honegger H, Hodler J et al (2005) Primary lymphoma of bone: MRI and CT characteristics during and after successful treatment. AJR Am J Roentgenol 184:185–192CrossRefPubMed
32.
Eissa HM, Allen CE, Kamdar K et al (2014) Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol 31:253–257CrossRefPubMed